2023-07-05 16:14:06 ET
- Therapeutics company Histogen ( NASDAQ: HSTO ) said on Monday that it has completed a review of its business, and plans to commence a process to explore strategic alternatives.
- The potential strategic alternatives may include an acquisition, merger, reverse merger, other business combination, sale of assets, financing alternatives, licensing, or other strategic transactions.
- The company has decided to pause further development of its programs.
- Also, the company said it does not intend to make any further disclosures on the strategic review process unless and until a specific course of action is approved by the board.
- Source: Press Release
For further details see:
Histogen plans to commence strategic alternatives process